Shots:

• The companies plan to file IND submission and initiate human clinical studies to evaluate neutralizing mAbs against COVID-19 in the US and China in Q2’2020
• The article is being published in Nature- reports the identification and characterization of two mAb’s CA1 and CB6 from the COVID-19 recovered patients
• CA1 and CB6 mAb’s have demonstrated substantial neutralization activity in vitro against SARS-CoV-2 while CB6 exhibits superior neutralizing activities against the virus by 3 logs in rhesus monkeys when administered one day after infection

 Ref: PRNewswire  | Image: Eli Lilly